Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolazamide-induced hepatic dysfunction.

T A LoIudice, J A Lang

    The American Journal of Gastroenterology
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Tolazamide can cause liver injury, confirmed by abnormal liver tests and biopsy showing inflammation and fibrosis. This case highlights a new type of sulfonylurea-related hepatic damage.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Changes in gastric contents in pigs fed a finely ground and pelleted or coarsely ground meal diet.

    Journal of animal science·1999
    Same author

    Transforming growth factor beta1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons.

    Journal of neurochemistry·1998
    Same author

    Transcriptional and posttranscriptional mechanisms regulate human renin gene expression in Calu-6 cells.

    The American journal of physiology·1996
    Same author

    Arterial oxygen saturation in healthy term neonates.

    European journal of pediatrics·1996
    Same author

    Laboratory restructuring: a move to self-directed teams. The experience at United Health Laboratories.

    Clinical laboratory management review : official publication of the Clinical Laboratory Management Association·1995
    Same author

    Tissue-specific expression of novel messenger ribonucleic acids cloned from a renin-expressing kidney tumor cell line (As4.1).

    Endocrinology·1995
    Same journal

    Calendar of Courses, Symposiums and Conferences.

    The American journal of gastroenterology·2026
    Same journal

    Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

    The American journal of gastroenterology·2026
    Same journal

    ACG Clinical Guideline: Colonic Diverticulitis.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    Continuing Medical Education Questions: July 2026.

    The American journal of gastroenterology·2026
    Same journal

    2026 CME Information.

    The American journal of gastroenterology·2026
    See all related articles

    Area of Science:

    • Hepatology
    • Pharmacology
    • Toxicology

    Background:

    • Sulfonylureas are commonly prescribed oral hypoglycemic agents.
    • Drug-induced liver injury (DILI) is a significant concern in pharmacotherapy.
    • Previous reports have linked some sulfonylureas to hepatic dysfunction.

    Observation:

    • A patient developed liver injury during treatment with tolazamide.
    • Clinical presentation included elevated liver enzymes: alkaline phosphatase, 5' nucleotidase, and serum glutamic oxaloacetic transaminase.
    • Liver biopsy revealed severe portal inflammation, bile duct proliferation, and early fibrosis.

    Findings:

    • The observed liver injury pattern is consistent with tolazamide toxicity.
    • Histopathological findings suggest a distinct form of drug-induced hepatic damage.

    Related Experiment Videos

  • This case contributes to the understanding of sulfonylurea-associated hepatotoxicity.

    • Implications:

    • Tolazamide should be considered a potential cause of drug-induced liver injury.
    • Further investigation into the mechanisms of sulfonylurea hepatotoxicity is warranted.
    • Clinicians should monitor liver function in patients treated with tolazamide and other sulfonylureas.